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Introduction: Chemokine-directed migration is crucial for homing of regenerative cells to the infarcted heart and
correlates with outcomes of cell therapy trials. Hence, transplantation of chemokine-responsive bone marrow cells
may be ideal for treatment of myocardial ischemia. To verify the therapeutic activity of bone marrow mononuclear
cells (BM-MNCs) selected by in vitro migration towards the chemokine stromal cell-derived factor-1 (SDF-1) in a
mouse model of myocardial infarction (MI), we used BM-MNCs from patients with previous large MI recruited in the
TransACT-1&2 cell therapy trials.
Methods: Unfractioned BM-MNCs, SDF-1-responsive, and SDF-1-nonresponsive BM-MNCs isolated by patients
recruited in the TransACT-1&2 cell therapy trials were tested in Matrigel assay to evaluate angiogenic potential.
Secretome and antigenic profile were characterized by flow cytometry. Angiogenin expression was measured by
RT-PCR. Cells groups were also intramyocardially injected in an in vivo model of MI (8-week-old immune deficient
CD1-FOXN1nu/nu mice). Echocardiography and hemodynamic measurements were performed before and at 14 days
post-MI. Arterioles and capillaries density, infiltration of inflammatory cells, interstitial fibrosis, and cardiomyocyte
proliferation and apoptosis were assessed by immunohistochemistry.
Results: In vitro migration enriched for monocytes, while CD34+ and CD133+ cells and T lymphocytes remained
mainly confined in the non-migrated fraction. Unfractioned total BM-MNCs promoted angiogenesis on Matrigel more
efficiently than migrated or non-migrated cells. In mice with induced MI, intramyocardial injection of unfractionated or
migrated BM-MNCs was more effective in preserving cardiac contractility and pressure indexes than vehicle or
non-migrated BM-MNCs. Moreover, unfractioned BM-MNCs enhanced neovascularization, whereas the migrated
fraction was unique in reducing the infarct size and interstitial fibrosis. In vitro studies on isolated cardiomyocytes
suggest participation of angiogenin, a secreted ribonuclease that inhibits protein translation under stress conditions, in
promotion of cardiomyocyte survival by migrated BM-MNCs.
Conclusions: Transplantation of bone marrow cells helps post-MI healing through distinct actions on vascular cells
and cardiomyocytes. In addition, the SDF-1-responsive fraction is enriched with angiogenin-expressing monocytes,
which may improve cardiac recovery through activation of cardiomyocyte response to stress. Identification of factors
linking migratory and therapeutic outcomes could help refine regenerative approaches.* Correspondence: Paolo.Madeddu@bristol.ac.uk
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Bone marrow mononuclear cells (BM-MNCs) are pre-
dominant in cell therapy trials of myocardial infarction
(MI) and heart failure [1]. Recent reviews and meta-
analyses indicate that BM cell therapy is safe and leads
to tangible improvements in cardiac function, ventricular
remodeling and clinical outcomes, including incidence
of death, recurrent MI and stent thrombosis [2-4].
In spite of these encouraging results, the heterogeneity
of BM cell products and complexity of intercellular in-
teractions in the treated myocardium fuels major con-
troversies in the field. Originally supposed to induce de
novo cardiomyogenesis [5], BM cells are now mainly ac-
knowledged as promoters of reparative neovasculariza-
tion [6]. Paracrine communication of transplanted cells
with endothelial cells, resident cardiomyocytes and pro-
genitor cells (PCs) recruited from cardiac or distant
niches, but also crosstalk between the different cell types
within the applied preparation, boosts vascular repair
and also conveys survival cues to cardiac cells in the area
at risk [6-10]. The extent to which specific BM cell sub-
fractions participate and possibly synergize to determine
distinct therapeutic benefits remains a matter of debate
[11-13]. Furthermore, risk factors and comorbidities
cause pauperization of BM-PCs and shift to the myeloid
lineage, together with reduction of regenerative potential
and immune competence [8,14-16]. Therefore, trans-
plantation of unselected autologous preparations bears
the risk that presence of useless or even harmful cells
may hamper the activity of few regenerative cells. In
addition, isolation protocols may variably impact on BM
cell viability and functionality, thus calling for introduc-
tion of quantity and quality control standards [17].
Following these considerations, immunomagnetically
and antigenically sorted CD133+ or CD34+ PCs have
been proposed for cardiovascular cell therapy [18-20].
Another attractive option is to select cells on the basis
of their functional qualities. This is supported by the ob-
servation that the in vitro migratory activity towards the
chemokine stromal cell-derived factor 1 (SDF-1) predicts
the outcome of pre-clinical and human BM cell therapy
studies [21,22]. Following this logic, we have developed a
cell sorting method based on responsiveness to chemo-
tactic cues. We reported that peripheral blood (PB)
MNCs that migrate in response to chemoattractants such
as SDF-1 or bradykinin are enriched for CD133+ and
CD34+ PCs, release higher amounts of pro-angiogenic cy-
tokines, and generate more nitric oxide and less super-
oxide in comparison with non-migrated PB-MNCs
[23,24]. Therefore, the in vitro migration assay not only
recapitulates a fundamental pathophysiological mechan-
ism implicated in tissue repair [25,26], but also provides
additional insights into the molecular profile of distinct
cell types associated with directed cell motility.The primary objective of this study was to test if mi-
gration towards SDF-1 allows isolating of therapeutically
valuable cells from the BM of cardiovascular patients
with a history of previous MI. To this end, we compared
unfractioned total BM-MNCs and SDF-1-responsive or
SDF-1-nonresponsive BM-MNCs with regard to anti-
genic characteristics, in vitro functions, and therapeutic
activity in a mouse model of MI. Furthermore, we in-
vestigated if differences in secreted pro-angiogenic and
pro-survival factors may account for specific thera-
peutic activities of fractioned cells. In view of clinical
translation, BM-MNCs were obtained from coronary
artery disease patients undergoing the Bristol-based cell
therapy surgical trials TransACT-1 and TransACT-2.
Newly results indicate that BM cells from patients with
large recent or chronic MI contain populations able to
promote cardiac repair by distinct mechanisms involv-
ing angiogenesis and cardiomyocyte response to stress.
Methods
Detailed Methods are provided in Additional file 1.
Patients
The study was performed in accordance with the declar-
ation of Helsinki (1964) and subsequent amendments
and approved by the Bristol National Health Service eth-
ical committee. BM specimens were obtained blindly
from risk-profiled coronary artery disease patients par-
ticipating in the Bristol-based TransACT-1&2 autolo-
gous BM cell therapy trials (RA; recruitment completed
at the Bristol Heart Institute in January 2014). All neces-
sary informed consent, including acceptance to partici-
pate in the study, was obtained from any patients
involved in the study. Patients were selected according
to strict cardiac magnetic resonance imaging criteria
identifying a previous large MI, requiring coronary ar-
tery bypass grafting (TransACT-1) or left ventricular res-
toration surgery (TransACT-2). Key inclusion criteria of
the TransACT trials and the anonymized cardiovascular
risk profile of the BM donors recruited to this study are
reported in Additional file 1: Tables S1 and S2. Details of
the clinical trials from which the study is generated are
available online [27]. In addition, as a “healthy” reference,
BM leftover was obtained from two male individuals (aged
56 and 58 years with no evidence of cardiovascular dis-
ease) at the occasion of orthopedic surgery for hip trans-
plantation (covered by National Health Service ethical
approval, REC number: 14/WA/1005).
Isolation of bone marrow mononuclear cell fractions
MNCs were isolated by density centrifugation of fresh
human BM cell suspension (5 mM phosphate-buffered
saline (PBS)-ethylenediaminetetraacetic acid (EDTA)) on
Histopaque 1077 (Sigma, Poole, UK). Migration was
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mL) as chemoattractant [23,24]. In some experiments,
bradykinin (100 ng/mL) was also used as a stimulus for cell
migration. Migration medium without chemoattractant
(vehicle) was employed to control for unspecific cell mo-
tility. After 18 hours of migration, non-migrating and mi-
grating populations were obtained separately by washing
the upper and lower chambers and respective sides of the
migration filter three times with 1 × PBS containing 5 mM
EDTA. Cell viability was assessed by trypan blue staining.
In selected experiments, BM-MNCs were exposed to
SDF-1 or vehicle for the same duration of migration.
Flow cytometry
Unfractioned, non-migrated (SDF-1non, vehnon) and mi-
grated (SDF-1mig, vehmig) BM-MNCs from 10 individual
patients were stained for surface antigen expression and
analyzed on a FACS Canto II flow cytometer equipped
with FACS Diva software (BD Biosciences, Oxford, UK).
Fluorescence minus one staining controls were per-
formed to define positivity.
Matrigel assay
In vitro network formation by human umbilical vein
endothelial cells (HUVECs) was studied using a Matrigel
assay in the presence of unfractioned or SDF-1mig BM-
MNCs. Analysis of cumulative branch length was per-
formed using ImagePro software (Media Cybernetics,
Rockville, MD, USA).
Measurement of growth factors and cytokines
The paracrine activity of unfractioned and SDF-1mig BM-
MNCs was quantified by measuring the levels of chemo-
kines (interleukin (IL)-1β, IL-2, IL-3, IL-4, IL-6, IL-7, IL-8,
IL-9, IL-10, IL-12, IL-13, and RANTES), chemoattractant
factors (granulocyte colony-stimulating factor, granulocyte
macrophage colony-stimulating factor, and monocyte
chemoattractant protein (MCP-1)), and molecules associ-
ated with inflammation and angiogenesis (macrophage in-
flammatory protein 1α/β, FASL, tumor necrosis factor α,
interferon γ, vascular endothelial growth factor (VEGF),
basic fibroblast growth factor (bFGF), and angiogenin in
cell conditioned media (flow cytometry bead array; BD
Biosciences, Oxford, UK). Nine individual samples were
studied in duplicate. Furthermore, we used an enzyme-
linked immunosorbent assay (ELISA; R&D, Abingdon,
UK) for quantitative measurement of human angiogenin
in conditioned media (n = 7 patients).
Angiogenin expression in sorted monocyte subpopulations
BM cells were suspended in PBS-EDTA 5 mM and fil-
tered through a strainer (70 μm sieve). MNCs were iso-
lated by Ficoll Histopaque 1077 (Sigma) gradient. The
MNC layer was carefully collected and washed twice inPBS. Cells were stained with PE-conjugated CD3 (MACS
Milteny, Bisley, Surrey, United Kingdom), APC-
conjugated CD14 (R&D), and PerCP-conjugated CD16
(BioLegend, London, United Kingdom) antibodies for 30
minutes at 4°C. After washing, 5 × 107 MNCs cells were
acquired and sorted by Influx™ Cell sorter (BD) into
four different groups: CD3−CD14+CD16+, CD3−CD14
+CD16−, CD3−CD14−CD16+ and CD3−CD14−CD16−
cells. The expression of angiogenin was then verified in
the sorted populations by RT-PCR (n = 4 patients).
Cell therapy in a murine myocardial infarction model
Animal experiments were performed in accordance with
the Guide for the Care and Use of Laboratory Animals
(Institute of Laboratory Animal Resources, National
Academy of Sciences, Bethesda, MD, USA, 1996) and
under ethical licence from the UK Home Office (licence
holder PM, University of Bristol). MI was induced in 8-
week-old immune deficient CD1-FOXN1nu/nu mice
(Charles River, Wilmington, MA, US) by ligation of the
left anterior descending coronary artery as described pre-
viously [28,29]. This was followed by injection of 3 × 105
unfractioned, SDF-1non or SDF-1mig BM-MNCs, or cell-
free EBM-2 (vehicle) at three different sites along the in-
farct border zone with a final volume of 10 μL at each site.
Echocardiography and hemodynamic measurements
Measurements of dimensional and functional parameters
were performed before and 14 days post-MI using a high-
frequency, high-resolution echocardiography system
(Vevo 770, Visual Sonics, Toronto, Canada) [28,29]. Fol-
lowing the final echocardiography session, intraventricular
pressure was measured using a high-fidelity 1.4F trans-
ducer tipped catheter (Millar Instruments, Houston, TX,
US) inserted into the left ventricle through the right ca-
rotid artery. Measurement of echocardiography and pres-
sure indexes was performed in 14 mice per group.
Immunohistochemistry
Hearts were stopped in diastole by intramyocardial in-
jection of cadmium chloride, washed free of blood by
retrograde perfusion with PBS-2% EDTA solution,
followed by fixation with 4% paraformaldehyde solution
overnight. Cryosections were made at 10 μm thickness,
placed on superfrost ultra plus (Thermo, Braunschweig,
Germany) slides, air dried for 30 minutes and immuno-
stained for the assessment of capillary and arteriole
densities, infiltration of inflammatory cells, interstitial fi-
brosis and cardiomyocyte proliferation and apoptosis
(see Additional file 1).
Immunocytochemistry of isolated cardiomyocytes
Adult rat cardiomyocytes were isolated using collagenase
perfusion and used immediately for experiments. Cells
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media mixed with concentrated conditioned media, which
were collected from SDF-1non or SDF-1mig or unfractioned
BM-MNCs, or EBM-2 basal medium. Synthetic angio-
genin (BD, 10 ng/mL) was used as a positive control. In
inhibition experiments, recombinant human ribonuclease/
angiogenin inhibitor 1 (RNH1; OriGene, Rockville, MD,
US) was added to the conditioned medium 1 hour prior
to incubation with cardiomyocytes. Cardiomyocytes were
fixed and immunostained for the stress granules marker
eIF3 (goat polyclonal; Santa Cruz, Dallas, TX, US),
α-sarcomeric actinin (mouse monoclonal; Sigma) and
4′,6-diamidino-2-phenylindole to identify nuclei. For cell
viability study, cardiomyocytes were incubated for 15
hours in hypoxia with unconditioned medium or condi-
tioned medium from SDF-1mig BM-MNCs, in the pres-
ence or absence of RNH1. At the end of the incubation
period, rod-shaped cardiomyocytes still attached to the
culture-dish were counted as viable cells, while round cells
detached from the dish were evaluated as dead cells.
Experiments were performed in duplicate. At least 800
cells were analyzed for each condition.
Statistical analysis
All results are presented as mean ± standard error of the
mean, or median and range, from three or more experi-
ments as indicated. For comparison of multiple groups,
analysis of variance or Friedman test were used after veri-
fication of Gaussian distribution. Statistical significance
was then determined by paired or unpaired t-tests asFigure 1 In vitro migration allows for separation of viable bone marrow m
migrated BM-MNCs, following exposure to the chemoattractant stromal ce
error of the mean from 10 individual donors, with migration (migr) being p
median values, 10th and 90th percentiles, and minimum/maximum values
was made between unfractioned total BM-MNCs, either freshly collected (unfra
migration assay (unfractioned post), and BM-MNCs that were harvested fr
following stimulation with SDF-1 or its vehicle. Trypan blue-positive BM-M
or directed migration selects for viable cells. **P < 0.001, versus unfractioned Bappropriate. Furthermore, best-fit and stepwise regression
analyses were performed to verify the predictive value of
clinical and laboratory data and cell phenotype on out-
come endpoints. Variables were entered into the equation
only if they satisfied the following criteria: F-to-enter, de-
fault value = 3.84; probability of F-to-enter, default value =
0.05. The cumulative effect of these relationships was il-
lustrated by Radar plot. Survival rate was calculated by
Kaplan-Meyer test. A P value <0.05 was considered sig-
nificant. Stated n values represent biological replicates.
Results
Stromal cell-derived factor 1-induced migration enriches
for viable bone marrow mononuclear cells
Quantitative analysis of migration assays indicates that
BM-MNCs from patients with previous large MI are
functionally responsive to SDF-1. In fact, the number of
BM-MNCs that migrated towards SDF-1 was greater
than that of BM-MNCs spontaneously migrating upon
exposure to the vehicle (P < 0.01; Figure 1A).
Evaluation of viability is a fundamental step in the
quality control assessment of cell therapy products. An
average 5.7% (range 2.0 to 19.1%) of unfractioned BM-
MNCs stained positive for trypan blue, a dye that tra-
verses the membrane in a dead cell. This figure did not
change after storage of cells in their original medium for
the duration of the migration assay (unfractioned post,
7.6%; range 5.2 to 19.0%; Figure 1B). Importantly, trypan
blue-positive cells were fewer in the vehmig (3.4%; range
2.0 to 7.9%) and SDF-1mig fractions (2.4%; range 0.7 toononuclear cells (BM-MNCs). (A) Bar graph shows the percentage of
ll-derived factor 1 (SDF-1) or vehicle (veh). Values are means ± standard
erformed in duplicate. **P < 0.01, versus vehmig. (B) Box plots show
of trypan blue-positive BM-MNCs from the same experiment. Comparison
ctioned pre) or incubated in their original medium for the duration of
om the upper (non) and lower chamber (migr) of the migration assay
NCs are fewer in the migrated fractions, indicating that spontaneous
M-MNCs, ΦΦP < 0.01, versus the respective non-migrated fraction.
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BM-MNCs; Figure 1B). A similar migration-induced en-
richment in viable cells was obtained using bradykinin
as a chemoattractant in the in vitro assay (3.0%; range 0
to 7.5%). Altogether, these data indicate that either spon-
taneous or chemokine-directed migration results in a
quality-improved BM cell product.
Antigenic and molecular characteristics of unfractioned
and fractioned bone marrow mononuclear cells
We next assessed the cellular composition of unfrac-
tioned, migrated and non-migrated populations by flow
cytometry. (Gating procedures are shown in Additional
file 1: Figure S1.) Granulocytes, which represent approxi-
mately 60% of the unfractioned BM population, remained
similar in both migrated and non-migrated fractions (data
not shown). In contrast, a striking difference between the
two fractions was observed with regard to lymphocytes,
monocytes, and cells expressing progenitor markers
(Figure 2A-D). When considering the percent changes of
specific subpopulations before and after migration, we
found that spontaneous migration towards vehicle de-
pletes CD3+ lymphocytes as well as CD34+ and CD133+
PCs, co-expressing the VEGF receptor KDR or the SDF-1
receptor CXCR4 (Figure 2E,G). Moreover, SDF-1 stimula-
tion leads to the enrichment of classical (CD14++CD16−),
intermediate (CD14++CD16+) and non-classical (CD14
+CD16++) monocytes in the migrated fraction (Figure 2F,H).
Similar changes in cellular composition were observed
when using bradykinin as a chemoattractant in the migra-
tion assay (Additional file 1: Figure S2). Regression analysis
identified an inverse correlation between the abundance of
both CD34+ and CD133+ PCs in the unfractioned BM-
MNC population and patient age (R2 = 0.705 and 0.747, re-
spectively; P < 0.01). However, we could not find any other
associations between cardiovascular risk profile and enrich-
ment/depletion of BM-MNCs following migration.
Verification of the migration assay in BM cells from
subjects without a cardiovascular disease background con-
firms the depletion of CD3+ lymphocytes and CD34+ and
CD133+ PCs along with enrichment of CD14++CD16−,
CD14++CD16+ and CD14+CD16++ monocytes in the SDF-
1-attracted fraction (Additional file 1: Figure S3).
Support of endothelial tube formation and paracrine
factors secreted by unfractioned and fractioned bone
marrow mononuclear cells
We next investigated if differences in cellular compos-
ition before and after migration are associated with
changes in pro-angiogenic activity on Matrigel. Unfrac-
tioned BM-MNCs augmented the network forming
capacity of HUVECs (P < 0.01 versus HUVECs alone;
Figure 3). Regression analysis indicates that the in vitro pro-
angiogenic activity of unfractioned BM-MNCs is predictedby the relative abundance of CD34+ and CD133+ PCs
(P < 0.02 for both cells types) and CD14++CD16− (P < 0.01)
and Tie2+CD16+ monocytes (P < 0.05). In contrast, SDF-
1mig cells, which are enriched in monocytes but depleted of
CD34+ and CD133+ PCs, did not support endothelial net-
work formation (P < 0.01 versus unfractioned, not signifi-
cant versus HUVECs alone; Figure 3). These data suggest
that the cooperation of progenitor populations with other
cell subfractions is essential for promotion of in vitro
network formation by HUVECs.
BM-MNCs secrete growth factors and cytokines that in-
fluence angiogenesis in vitro and in vivo [10]. Using a cy-
tometric bead array that measures a variety of cytokines
and growth factors implicated in reparative angiogenesis,
we found that SDF-1mig BM-MNCs release angiogenin
more abundantly than unfractioned BM-MNCs (P < 0.01),
while the latter tend to release more VEGF, tumor necro-
sis factor-α and RANTES (Additional file 1: Figure S4A).
Regression analysis revealed that the association of differ-
ent secreted factors (for example, VEGF, IL-8, angiogenin
and MCP-1) predicts the increase in endothelial network
formation induced by unfractioned BM-MNCs (P < 0.01).
This cooperative interaction is also illustrated by the radar
plot generated by connecting the F-to-enter values from
regression analyses (Additional file 1: Figure S4B).
In order to verify the levels of angiogenin with a more
sensitive method, we assayed the factor by a specific
ELISA. The assay confirmed higher levels of angiogenin
in conditioned media of SDF-1mig cells (90 ± 10 pg/mL per
million cells) as compared with the respective unfractioned
(30 ± 4; P < 0.001) and SDF-1non cells (17 ± 2; P < 0.001;
n = 7 donors; Figure 4A). RT-PCR verified that SDF-
1mig cells express more angiogenin that unfractioned
(3.2-fold) and SDF-1non cells (4.7-fold) (P < 0.05 and P < 0.01,
respectively; n = 4 donors; Figure 4B). In contrast, no
change in angiogenin protein and mRNA levels was ob-
served when exposing unfractioned BM-MNCs to SDF-1
in a test tube for the duration of the migration assay, thus
suggesting that directed migration to, rather than SDF-1
itself, is responsible for the observed difference in angio-
genin expression (data not shown). In order to identify the
BM-MNC fraction that expresses angiogenin, we sorted
total BM cells according to the gating procedure illus-
trated in Figure 4C. We found that CD14+CD16+ and
CD14+CD16− monocytes express five-fold and three-fold
higher angiogenin levels as compared to non-monocyte
populations. These data newly identify angiogenin-
expressing monocytes in the migratory element of BM ob-
tained from MI patients.
In vivo therapeutic activity of unfractioned and
migration-fractioned bone marrow mononuclear cells
We next asked if BM cell populations selected by SDF-
1-induced migration differ from total BM cells with
Figure 2 (See legend on next page.)
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Figure 2 In vitro migration leads to enrichment of monocytes and depletion of progenitor cells. (A-D) Bar graphs show the percentage of (A)
lymphocytes and classical monocytes, (B) intermediate and non-classical monocytes and (C,D) progenitor cells. (E-H) Bar graphs show the enrichment/
depletion of antigenically defined cell populations in migrated and non-migrated fractions following exposure to (F,H) stromal cell-derived factor 1
(SDF-1) or (E,G) vehicle (veh). Values are means ± standard error of the mean, n = 10 in each group. ΦP< 0.05, ΦΦP < 0.01, versus unfractioned; #P< 0.05,
##P< 0.01, versus corresponding vehicle group; *P< 0.05, **P< 0.01, versus corresponding non-migrated group. BM-MNC, bone marrow mononuclear cell.
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we injected SDF-1non, SDF-1mig or unfractioned BM-
MNCs from three donors into the infarct border zone of
immunodeficient mice.
As shown in Additional file 1 (Figure S5), cell therapy
improves post-MI survival rate as compared with vehicle
(P < 0.02), with no difference between migrated, non-
migrated or unfractioned BM-MNCs. No differences
were detected for echocardiographic parameters between
recipient groups at day 0 (data not shown). Analysis of
variance detected an effect of cell therapy with regard to
left ventricular anterior wall thickness (P < 0.0001), left
ventricular end systolic volume (P < 0.05), left ventricu-
lar ejection fraction (LVEF; P = 0.01), and cardiac out-
put (P < 0.05) (Figure 5A-I), with no difference among
donors. Comparison of the effects induced by distinct
BM-MNC fractions by Tukey’s test indicates that
unfractioned and SDF-1migr BM-MNCs induce compar-
able improvements in left ventricular anterior wall
thickness (P < 0.001 versus vehicle for both comparisons;
Figure 5A,B), LVEF (P < 0.05 versus vehicle for bothFigure 3 Comparison of in vitro endothelial network formation
potentiation by unfractioned bone marrow mononuclear cells (BM-MNCs).
Bar graph shows that unfractioned BM-MNCs support in vitro network
formation by human umbilical vein endothelial cells (HUVECs) more
efficiently than stromal cell-derived factor 1 migrated (SDF-1mig)
counterparts. BM-MNCs were obtained from 10 donors for matched
comparisons. Values are means ± standard error of the mean.
**P < 0.01, versus HUVECs; ΦP < 0.05, ΦΦP < 0.01, versus unfractioned
BM-MNCs; #P < 0.05, versus vehicle migrated (Vehmig).comparisons; Figure 5H), and cardiac output (P < 0.05 ver-
sus vehicle for both comparisons; Figure 5I). In contrast,
there was no difference between groups that received
SDF-1non cells or vehicle with regard to indexes of con-
tractility (that is, LVEF and cardiac output).
Cell therapy improved left ventricular end diastolic
pressure, and maximum and minimum changes in devel-
oped pressure (P < 0.0001 versus vehicle; Figure 5J,K),
with no difference among donors. When examining the
effects of distinct cell fractions, we found that injections
of unfractioned or SDF-1migr BM-MNCs blunts the
post-MI increase in left ventricular end diastolic pres-
sure (P < 0.001 and P < 0.05 versus vehicle, respectively),
while SDF-1non BM-MNCs were ineffective (not signifi-
cant versus vehicle, P < 0.01 versus unfractioned BM-
MNCs; Figure 5J). Likewise, SDF-1non BM-MNCs were
inferior to total BM-MNCs in preserving the maximum
and minimum changes in developed pressure indexes
(Figure 5K). Taken together, these data indicate that in-
jections of unfractioned or migrated BM-MNCs im-
proves left ventricular remodeling and contractility to a
greater extent than the non-migrated counterparts.
We next verified if the denoted hemodynamic im-
provement is associated with a reduction of the scar and
increase in reparative neovascularization. Masson tri-
chrome staining showed a reduction in infarct scar and
peri-infarct interstitial fibrosis in the group that received
SDF-1migr BM-MNCs, but not in the other cell therapy
groups (Figure 6A,B). Immunohistochemistry analyses
denoted no group difference with regard to the abun-
dance of apoptotic cardiomyocytes, but an overall
increase in Ki-67-positive cardiomyocytes in the peri-
infarct zone of the cell therapy groups compared with
vehicle (Figure 6C,D).
Analysis of the coronary microvasculature showed that
mice receiving cell therapy exhibit higher levels of capil-
laries and arterioles than mice given vehicle (P < 0.01;
Figure 6E-S). Post-hoc analysis by Tukey’s test revealed
the superior pro-angiogenic activity of unfractioned
BM-MNCs versus SDF-1non or SDF-1mig cells, in line
with results of in vitro network formation on Matrigel.
Histological studies also revealed an effect of cell ther-
apy on the number of infiltrating CD45+ cells (unfrac-
tioned, 21 ± 2; SDF-1non, 28 ± 2; SDF-1mig, 25 ± 2;
versus vehicle, 52 ± 4 cells/mm2; P < 0.01 for all com-
parisons), with no difference between cell therapy
groups.
Figure 4 Expression of angiogenin in migrated and sorted bone marrow cell populations. (A) Immunoreactive angiogenin levels in conditioned
media from unfractioned, stromal cell-derived factor 1 non migrated (SDF-1non) and migrated (SDF-1mig) mononuclear cells (MNCs; n = 7 per
group). (B) Angiogenin mRNA levels of unfractioned, SDF-1non and SDF-1mig MNCs (n = 4 per group). Values are means ± standard error of the
mean. *P < 0.05, **P < 0.01, ***P < 0.001, versus unfractioned; #P < 0.05, ###P < 0.001, versus SDF-1non. (C) Angiogenin mRNA levels in sorted bone
marrow cells. (i-iii) Gating strategy to sort BM monocyte subpopulations: human MNCs isolated by Ficoll gradient from BM were analyzed by flow
cytometry (i). Lympho-monocyte population was gated and analyzed according to CD3 positivity (ii) in order to exclude lymphocytes. Cells negative
for CD3 were gated and further analyzed for monocytes markers CD14 and CD16 (iii). Four distinct populations were sorted: CD14−/CD16+ (pink gate),
CD14+/CD16+ (green gate), CD14+/CD16− (red gate), negative cells (black gate). Angiogenin levels were measured in triplicate by RT-PCR (iv). Values are
means ± standard error of the mean. **P < 0.01, versus CD3−/CD14−/CD16− cells. FSC, forward-scattered light; SSC, side-scattered light; UBC, Ubiquitin C.
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SDF-1migr BM-MNCs exert similar therapeutic effects as
assessed by echocardiography and intraventricular pres-
sure measurements. However, only unfractioned cells
have pro-angiogenic activity, whereas SDF-1migr cells re-
duce infarct size and interstitial fibrosis.
Stromal cell-derived factor 1 migrated bone marrow
mononuclear cells induce the formation of stress
granules in hypoxic cardiomyocytes through an
angiogenin-mediated mechanism
Recent studies indicate that, under stress conditions,
angiogenin enzymatically generates tRNA-derived stress-
induced small RNA (tiRNA) in cytoplasmic stress granules
(SGs), thereby restricting translation to the synthesis of
proteins necessary for cell survival [30]. Here, we investi-
gated if BM-MNC-secreted angiogenin may influencecardiomyocyte viability. Immunocytochemistry analyses
of rat cardiomyocytes exposed to hypoxia in the pres-
ence of BM-MNC-conditioned media showed an in-
crease in the percentage of cells expressing eIF3
positive SGs (analysis of variance, P < 0.001 versus un-
conditioned medium; Figure 7A,B). Tukey’s multiple
comparison test indicates an increase of SGs in cardio-
myocytes exposed to the SDF-1mig cell-conditioned
medium compared to cardiomyocytes exposed to SDF-
1non (P < 0.01) or unfractioned cell-conditioned media
(P < 0.05). The effect induced by SDF-1mig cells was
similar to that observed by incubating cardiomyocytes
with synthetic angiogenin (positive control).
Importantly, the induction of SGs by SDF-1mig cell-
conditioned medium (P< 0.05 versus unconditioned medium)
was reduced by co-incubation with RNH1, a ribonuclease/
angiogenin inhibitor (P< 0.05 versus conditioned medium),
Figure 5 Intra-myocardial injection of unfractioned and migration-enriched bone marrow mononuclear cells (BM-MNCs) improves echocardiography
endpoints in a immune-deficient mouse model of myocardial infarction. Bar graphs show the effect of unfractioned, stromal cell-derived factor
1 (SDF-1) migrated (migr) or non-migrated (non) BM-MNCs from three different donors on (A-I) indexes of contractility and (J,K) intraventricular
pressure in immunodeficient mice with myocardial infarction. N = 14 mice per group for all the measured indexes. *P < 0.05, **P < 0.01, ***P < 0.001,
versus vehicle; ΦP < 0.05, ΦΦP < 0.01, ΦΦΦP < 0.001, versus unfractioned BM-MNCs; ##P < 0.01, versus non-migrated BM-MNCs. CO, cardiac output; dP/dt,
maximum changes in developed pressure; LVAWd, left ventricular anterior wall thickness in diastole; LVAWs, left ventricular anterior wall thickness in
systole; LVEDP, left ventricular end diastolic pressure; LVEDV, left ventricular end diastolic volume; LVEF, left ventricular ejection fraction; LVESV,
left ventricular end systolic volume; LVPWd, left ventricular posterior wall thickness in diastole; LVPWs, left ventricular posterior wall thickness
in systole; SV, stroke volume.
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in the augmentation of cardiomyocyte stress response
(Figure 7C). Additionally, SDF-1mig cell-conditioned
medium increases the viability of hypoxic cardiomyocytes,
with this effect being reduced by RNH1 (Figure 7D).
Altogether, these data indicate a novel cardioprotective ef-
fect of migrating BM cells, involving angiogenin-mediated
stress response in hypoxic cardiomyocytes.
Discussion
Results of the present study indicate that migration-based
selection separates two distinct fractions from total BM
cells of patients with previous MI: the non-migrated
component contains an abundance of lymphocytes and
CD34+/CD133+ PCs, while the migrated element is more
enriched with classical, intermediate and non-classicalmonocytes. Furthermore, intramyocardial injection of
unfractioned or migrated cells induces similar thera-
peutic benefits in a murine model of MI, but through
different mechanisms. As expected, unfractioned cells
promote reparative angiogenesis; in contrast, we show
for the first time that SDF-1migr cells reduce the infarct
size and peri-infarct fibrosis and exert cardiac protection
through the release of angiogenin and potentiation of
stress response in hypoxic cardiomyocytes. The present
study was limited to 14 days post-MI, as the a priori end-
point was to discriminate differences in early reparative
responses to BM cell therapy that can be revealed by the
migration-based fractioning. More investigation is neces-
sary to determine the impact of the fractioning approach
on prevention of late cardiac remodeling and heart
failure.
Figure 6 (See legend on next page.)
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Figure 6 Effect of cell therapy on infarct size, interstitial fibrosis and peri-infarct vascularization. (A) Infarct size assessed at 2 weeks after myocardial
infaction induction and injection of bone marrow mononuclear cells (BM-MNCs) or vehicle (VEH). (i) Representative images and (ii) bar graph showing
average values. (B) Peri-infarct interstitial fibrosis. (i) Representative image and (ii) bar graph showing average values. In the representative image and
insert magnification, cardiomyocytes are stained red, while the fibrotic tissue is stained blue. (C,D) Fraction of Tunel positive (C) and KI-67 positive (D)
cardiomyocytes. Representative images of immunostaining (i) and average values (ii). (E-S) Myocardial vascularization assessed by counting
the density of capillaries and arterioles in the LV peri-infarct zone. Representative immunohistochemistry images (E-P) and average values
(Q-S). White scale bar = 20 μm. N = 7 to 10 per group. Values are means ± standard error of the mean. *P< 0.05, versus vehicle; ++P < 0.01, versus
unfractioned; #P < 0.05; ##P < 0.01, versus SDF-1non. LV, left ventricular; SDF-1mig, stromal cell-derived factor 1 migrated; SDF-1non, stromal cell-derived
factor 1 non-migrated.
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have led to a marked improvement in the survival rate
of patients suffering from acute MI. However, due to the
permanent loss of viable myocardium, a large proportion
of survivors develop cardiac dysfunction, which calls for
novel regenerative treatments. To date, the most suc-
cessful clinical trials performing autologous BM-MNC
transplantation in MI patients achieved an improvement
of LVEF by up to 20% and a decrease in infarct size of
up to 30% [31-36]. However, when looking at meta-
analysis reports, the size of the beneficial effects has var-
ied grossly, often due to methodological differences. Sev-
eral studies have since attempted further refinement by
modulating the composition of the transplanted cells
with the aim of selecting for a presumed most efficient
cell type [37-41]. However, efforts have been often hin-
dered by functional limitations and weakened regenera-
tive capacity intrinsic to patient-derived cells [15,42-44].
In addition, cell damage can occur as result of harvest-
ing procedures and subsequent processing prior to
transplantation. The novel observation that migration
fractioning significantly increases the number of viable
cells from the total BM preparation and enriches for
cells endowed with specific reparative activity has there-
fore, in our opinion, a relevant translational value.
Cardiovascular risk factors and ageing induce quanti-
tative and functional defects in BM PCs. Consistently, in
the present study, the number of CD34+ PCs was influ-
enced by patient’s age, (that is, older patients had lower
CD34+ cell counts in total BM-MNCs). Another study
showed that age influences the number and colony-
forming capacity of circulating CD34+ PCs [45]. Further-
more, we have previously observed that migration to-
wards bradykinin enriches for pro-angiogenic PCs from
PB-MNCs of healthy donors. However, migration-based
enrichment for PCs was significantly blunted, although
not completed abrogated, in acute MI patients. In the
present study, conducted in patients with previous MI,
SDF-1-induced migration resulted in the depletion of
BM CD34+ and CD133+ PCs. The discrepant behavior
of BM- and PB-derived PCs is intriguing and may reflect
a “migratory immaturity” of BM-resident PCs, as op-
posed to circulating PCs which are already primed to
mobilization. Impaired CD34+ PC migration isreportedly associated with adverse events in patients
with MI. The migratory defect might be attributable to
the downregulation of receptor expression or the dys-
function of signaling pathways downstream of the re-
ceptor, as it has been reported for circulating cells
before [46-48]. In addition, increased cleavage of SDF-1
by circulating or cell membrane-bound proteases, like
dipeptidylpeptidase IV/CD26, might result in the loss of
its signaling capabilities [49]. Other possibilities include
the choice of stimulus and the time period allowed for mi-
gration. When testing those hypotheses, we did not ob-
serve any difference using bradykinin instead of SDF-1.
Likewise, similar results were obtained in experiments
where migration was performed for 6 or 18 hours (data
not shown).
Of note, we show that different cell populations within
the total BM-MNC fraction contribute together in
stimulation of angiogenesis. Separation of PC and mono-
cyte components by migration resulted in the loss of
pro-angiogenic activity. These findings might have high
translational value for cell therapy applications, in par-
ticular with respect to the choice of delivering BM cell
products directly or systemically [50]. They imply that
BM-derived cells from MI patients might not be able to
provide their key pro-angiogenic effect in the MI area if
delivered through a route (like the intracoronary delivery
approach, for example) that relies on cell intrinsic mi-
gration potential to reach the MI area. We additionally
found that lymphocytes are predominantly retained in
the non-migrated fraction. There is a lack of consensus
on the role played by lymphocytes in reparative pro-
cesses, as these cells have been reported either to inhibit
[51] or promote angiogenesis [52], including by shedding
of microvesicles, which in turn can stimulate vascular
growth [53]. However, the present study did not show
any association between lymphocytes and promotion of
in vitro angiogenesis by unfractioned BM cells.
Different secreted factors, including VEGF, IL-8, MCP-
1 and angiogenin, were complementary in stimulation of
in vitro angiogenesis by total BM cells. Surprisingly,
however, transplantation of unfractioned BM-MNCs or
SDF-1mig BM-MNCs, which are enriched with angiogenin-
expressing monocytes, promoted similar functional recov-
ery in a mouse MI model, but only the former improved
Figure 7 (See legend on next page.)
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Figure 7 Formation of stress granules (SGs) in hypoxic cardiomyocytes following stimulation with bone marrow mononuclear cell (BM-MNC)-
conditioned medium. (A) Box plots show median values, 10th and 90th percentiles, and minimum/maximum values of hypoxic cardiomyocytes
that express eIF3-positive SGs following stimulation with unconditioned medium or conditioned media from unfractioned, SDF-1non or SDF-1-mig
BM-MNCs. Human angiogenin was used as a positive control. Values are means ± standard error of the mean. ***P < 0.001, versus unconditioned
medium; #P < 0.001, versus unfractioned; +++P < 0.001, versus SDF-1non. (B) Representative fluorescent microscopy image of SGs. (C) Inhibition of
angiogenin by ribonuclease/angiogenin inhibitor 1 (RNH1) results in a reduction in the ability of SDF-1mig cell-conditioned medium to stimulate
the formation of SGs. Representative images of eIF3 granules in cardiomyocytes exposed to SDF-1mig BM-MNC-conditioned medium in the absence (i) or
presence (ii) of RNH1 inhibitor. Myocyte cytoplasm is labeled with alpha sarcomeric actinin (iii). Nuclei are depicted in blue (4′,6-diamidino-2-phenylindole;
DAPI). (iv) Graph showing average results. **P< 0.05, versus unconditioned medium (UCM); #P< 0.05, versus of SDF-1mig cell-conditioned medium (CM).
(D) Inhibition of angiogenin by RNH1 results in a reduction in the ability of SDF-1mig cell-conditioned medium to contrast cardiomyocyte death upon
exposure to hypoxia. Round-shaped cells indicate dead cells, while rod-shaped cells are viable cells. *P< 0.05, versus UCM; #P< 0.05, versus of SDF-1mig
cell CM. SDF-1mig, stromal cell-derived factor 1 migrated; SDF-1non, stromal cell-derived factor 1 non-migrated.
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1mig BM cells induced a significant reduction of the infarct
size and interstitial fibrosis, while unfractioned BM-MNCs
did not. Interestingly, a recent pre-clinical cell therapy
study in rats with acute MI using mesenchymal stem cells
(MSCs) transfected with an adenoviral vector carrying the
angiogenin gene (MSCAdANG) showed that angiogenin ex-
pression confers donor cells with high resistance to oxygen
deprivation and with increased capacity to reduce infarct
size, left ventricular remodeling and improve cardiac func-
tion [54]. At variance with our study, cell therapy with
MSCAdANG also induced reparative angiogenesis in the
peri-infarct zone [54]. However, it should be noted that
MSCAdANG secrete much higher levels of angiogenin
(~700 ng/mL) as compared with SDF-1mig BM-MNCs
(~100 pg/mL). The activity of angiogenin is relatively low
compared with that of other angiogenic factors. Therefore,
differences in angiogenin dosage may account for the dis-
tinction between MSCAdANG and SDF-1mig BM-MNCs
with regard to promotion of reparative angiogenesis.
Emerging evidence indicates that, besides inducing the
transcription of various angiogenic genes [30], angio-
genin promotes stress responses instrumental to cell sur-
vival under adverse conditions [55]. In particular,
angiogenin acts as an RNAase cleaving tRNAs into
stress-induced tiRNAs, which in turn suppress the syn-
thesis of housekeeping proteins by inhibiting mRNA
translation [56]. Translationally repressed messenger ri-
bonucleoproteins are then transiently stored in SGs,
which are dynamic structures that can be recycled as
cells recover from stress [57]. Importantly, translation of
IRES-dependent mRNAs, many of which are involved in
pro-survival and anti-apoptosis, is resistant to tiRNA-
dependent inhibition, thereby allowing stressed cells to
direct the translational machinery and residual energy to
functions instrumental to survival [58,59]. Additional
pro-survival mechanisms of angiogenin include an inter-
action with the p53, p21 and Bax pathway in cancer cells
[60]. In line with results on other cell types [57,61], we
report for the first time that exogenous angiogenin stim-
ulates the formation of SGs in isolated ratcardiomyocytes. Most importantly, we newly show that
SDF-1mig BM-MNCs express and release large amounts
of angiogenin and that the conditioned medium of these
cells enhances the formation of SGs in rat cardiomyo-
cytes exposed to hypoxia. This was associated with a re-
duction of cardiomyocyte death. An implication of
angiogenin in the formation of SGs in cardiomyocytes
exposed to SDF-1migr cell media is confirmed by the
finding that this effect is abrogated by an angiogenin in-
hibitor. Similarly inhibited was the improvement in car-
diomyocyte survival. These new data highlight a novel
mechanism that may contribute to cardiac protection
elicited by the migrating component of BM-MNCs. It
should be noted that, in our in vivo study, cell therapy
did not produce any significant reduction in cardiomyo-
cyte apoptosis at the level of the peri-infarct zone, as de-
tected by Tunel staining at 2 weeks post-MI.
Cardiomyocyte loss is prevalent in the early phase after
permanent coronary artery ligation and therefore any
benefit induced by cell therapy might have been under-
estimated in our study. Furthermore, it is not clear
whether angiogenin-induced protection derives from in-
hibition of “programmed, apoptotic” or “accidental, non-
apoptotic” cell death. More in-depth investigation is
warranted to address this aspect.
Sorting experiments newly show that, within BM-
MNCs, CD14+CD16+ monocytes express the highest
levels of angiogenin. Experimental evidence indicates
that healing of infarcted heart requires monocytes/mac-
rophages. Classical monocytes, recruited in the early
phase after an MI, degrade cellular debris and macro-
molecules at the infarct site, while non-classical mono-
cytes intervene later, modulating the formation of
granulation tissue and cardiac remodeling [8]. Previous
studies by Nahrendorf and colleagues have shown that
Ly-6Clo (mouse analogues of CD14+CD16+ monocytes)
promote myocardial healing via myofibroblast accumula-
tion, angiogenesis, and deposition of collagen [8]. Al-
though circulating levels did not change following MI
induction, the capacity of Ly-6Clo/CD14+CD16+ mono-
cytes to migrate into ischemic myocardium increased
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uted to the expression of different chemokine receptors,
including CX3CR1, CCR5 and the SDF-1 receptor
CXCR4. Due to their ability to sense migratory cues,
angiogenin-expressing monocytes could spread through
the peri-infarct area and exert protective effect on
stunned cardiomyocytes. Therefore, the expression of
chemokine receptors and pro-survival factors may repre-
sent a fundamental association for monocyte healing
capacity.
Conclusions
This study conducted on BM specimens of TransACT
cell therapy trials newly demonstrates that migratory
features of BM-MNCs are associated with distinct cardi-
oprotective modalities. These new findings improve
current understanding of mechanisms implicated in
spontaneous and cell therapy-induced cardiac repair. On
the other hand, this research was not designed to make
any assumption or prediction of the trial outcomes. The
TransAct studies compare the benefit of intramyocardial
delivery of BM CD133+ PCs or their medium, in com-
bination with surgical revascularization or ventricular re-
shaping in patients with previous MI, whereas here we
verified the therapeutic effect of BM subfractions in a
mouse model of acute MI induced by permanent coronary
artery ligation. While additional investigation is necessary
to confirm the actions of migrated and non-migrated frac-
tions in models of ischemia-reperfusion or chronic ische-
mia, this study highlights the mechanistic complexity of
current cell therapy and the requirement of standardized
cell products in future clinical trials.
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